Jazz Pharmaceuticals plc (J7Z) — Capital Reinvestment Ratio
Jazz Pharmaceuticals plc (J7Z) has a Capital Reinvestment Ratio of 0.05x as of March 2026, meaning it reinvests 0% of its operating cash flow (€408.20 Million) in capital expenditures (€19.70 Million). See Jazz Pharmaceuticals plc net asset quality index to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Jazz Pharmaceuticals plc Capital Reinvestment Ratio (2013–2025)
This chart tracks Jazz Pharmaceuticals plc's Capital Reinvestment Ratio across 13 annual periods. Check cash flow reinvestment rate of Jazz Pharmaceuticals plc to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Jazz Pharmaceuticals plc (2013–2025)
Year-by-year Capital Reinvestment Ratio for Jazz Pharmaceuticals plc from 2013 to 2025. For live market cap and broader valuation context, see Jazz Pharmaceuticals plc market cap and net worth.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.15x | €1.36 Billion | €209.75 Million | ▲ +349.3% |
| 2024 | 0.03x | €1.40 Billion | €48.07 Million | ▼ -12.5% |
| 2023 | 0.04x | €1.09 Billion | €42.96 Million | ▲ +72.3% |
| 2022 | 0.02x | €1.27 Billion | €29.05 Million | ▼ -35.7% |
| 2021 | 0.04x | €778.51 Million | €27.64 Million | ▲ +112.9% |
| 2020 | 0.02x | €899.65 Million | €15.00 Million | ▼ -67.7% |
| 2019 | 0.05x | €776.40 Million | €40.13 Million | ▲ +102.7% |
| 2018 | 0.03x | €798.90 Million | €20.37 Million | ▼ -39.0% |
| 2017 | 0.04x | €693.09 Million | €28.95 Million | ▼ -86.4% |
| 2016 | 0.31x | €592.39 Million | €181.58 Million | ▲ +353.5% |
| 2015 | 0.07x | €531.94 Million | €35.96 Million | ▼ -24.2% |
| 2014 | 0.09x | €407.61 Million | €36.35 Million | ▲ +157.8% |
| 2013 | 0.03x | €288.43 Million | €9.98 Million | — |